Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score-Reference-Cited by-同舟云学术

Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score

Published:2019-08-19 Issue:11 Volume:94 Page:1176-1184
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Sanfilippo Kristen M.¹²^ORCID,Luo Suhong¹,Wang Tzu‐Fei³,Fiala Mark⁴,Schoen Martin⁵,Wildes Tanya M.⁴^ORCID,Mikhael Joseph⁶^ORCID,Kuderer Nicole M.⁷,Calverley David C.⁸,Keller Jesse¹⁵,Thomas Theodore¹,Carson Kenneth R.¹⁹,Gage Brian F.¹⁰

Affiliation:

1. Division of Hematology/OncologyVeterans Administration St. Louis Health Care System St. Louis Missouri

2. Division of HematologyWashington University School of Medicine Saint Louis St. Louis Missouri

3. Division of HematologyThe Ohio State University Comprehensive Cancer Center Columbus Ohio

4. Division of OncologyWashington University School of Medicine Saint Louis St. Louis Missouri

5. Division of Hematology/OncologySaint Louis University St. Louis Missouri

6. Applied Cancer Research and Drug Discovery,Translational Genomics Research Institute (TGen)City of Hope Cancer Center Duarte California

7. Advanced Cancer Research GroupUniversity of Washington Seattle Washington

8. Division of Hematology/OncologyVeterans Administration Portland Health Care System Portland Oregon

9. Flatiron HealthNew York New York

10. Division of General Medical SciencesWashington University School of Medicine Saint Louis St. Louis Missouri

Funder

National Cancer Institute

National Center for Advancing Translational Sciences

National Heart, Lung, and Blood Institute

Centers for Medicare and Medicaid Services

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25603

Reference56 articles.

1. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

2. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

3. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies

4. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis

5. Global Burden of Multiple Myeloma

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treating cancer-associated venous thromboembolism: A practical approach;European Journal of Cancer;2024-09

2. Venous Thromboembolism Post-allogeneic Hematopoietic Cell Transplant: Risk Factors, Incidence, and Outcomes;Thrombosis and Haemostasis;2024-07-15

3. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide;Blood Reviews;2024-07

4. The Risk of Venous Thromboembolism and Ischemic Stroke Stratified by VTE Risk Following Multiple Myeloma: A Korean Population-Based Cohort Study;Journal of Clinical Medicine;2024-05-11

5. Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis;Research and Practice in Thrombosis and Haemostasis;2024-05